Interestingly, reports also showed the efficacy of anti-CD19 FMC63-28Z CAR T-cells alone in treating patients with ALL, CLL, DLBCL, and MCL, in the absence of prior chemotherapy (88). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.